EMEA-002499-PIP02-19

Key facts

Active substance
Tafasitamab
Therapeutic area
Oncology
Decision number
P/0294/2019
PIP number
EMEA-002499-PIP02-19
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of diffuse large B-cell lymphoma
Route(s) of administration
Intravenous use
Contact for public enquiries
MorphoSys AG

E-mail: avril.mankel@morphosys.com
Tel. +49 8989 92726511

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating